The 74mcg once-daily product is indicated for the treatment of both ocular and nasal symptoms associated with seasonal allergic rhinitis and the treatment of nasal symptoms associated with perennial allergic rhinitis.
Sunovion vice chair Hiroshi Nomura said, "These treatments, together with the existing asthma and chronic obstructive pulmonary disease therapies in Sunovion’s respiratory franchise, demonstrate our continued commitment to providing a full range of medications for patients with respiratory illnesses."
The patients can track when their prescriptions should be refilled, with the aid of the built-in dose indicator.
The corticosteroid delivery system utilizes a 50mcL volume per spray and provides 24-hour relief, the company said.